Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.

  title={Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.},
  author={Ilfet Songun and Hein Putter and E. Meershoek klein Kranenbarg and Mitsuru Sasako and Cornelis J H van de Velde},
  journal={The Lancet. Oncology},
  volume={11 5},

Extent of lymphadenectomy has no impact on postoperative complications after gastric cancer surgery in Sweden

The majority of gastric cancer resections in Sweden have included only a limited lymphadenectomy (D0 and D1), which seemed to have no impact on postoperative morbidity or mortality.

Personalized Surgery for Gastric Adenocarcinoma: A Meta-analysis of D1 versus D2 Lymphadenectomy

Despite the addition of long-term survival data from the IGCSG, 5-year overall and nodal status survival was similar between D1 and D2 trials, and consideration should be made for more extensive lymph node dissection among patients with advanced stage.

Lymphadenectomy for gastric cancer at European specialist centres.

  • M. BencivengaL. Torroni G. De Manzoni
  • Medicine
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • 2020

Mortality and Morbidity and Disease Free Survival after D1 and D2 Gastrectomy for Stomach Adenocarcinomas.

It is indicated that D2 gastrectomy with pancreas preservation is not followed by significantly higher morbidity and mortality than D1 resection and D2 resection should be recommended as the standard surgical approach for resectable gastric cancer.

Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer (Br J Surg 2014; 101: 23–31)

The Italian study contributes to the view that D2 lymphadenectomy can be performed safely and adequately, producing 5-year survival results that help to close the gap between survival results reported from Asia and those from Europe.

Short-Term Outcome in Patients Undergoing Gastrectomy with D2 Lymphadenectomy for Carcinoma Stomach

The number of lymph nodes harvested was significantly more in D2 lymphadenectomy that resulted in a better staging and postoperative morbidity or mortality in patients undergoing D2ymphadenectomy was the same as in D1 lymph Adenectomy, suggesting gastrectomy with D2 thyroidectomy could be done safely.

Favoring D2-Lymphadenectomy in Gastric Cancer

A careful analysis of the available evidence indicates that D2-lymphadenectomy performed by adequately trained surgeons without resection of the pancreas and/or spleen, unless otherwise indicated, decreases Gastric Cancer Related Deaths and increases Disease Specific Survival.

Gastric Cancer in Poland – Clinical Characteristics and Results of Surgery

Retrospective analysis of the long-term results of the surgical-only management of GC patients may be useful in assessment of the quality of medical services, especially prior to introduction of multimodal therapy.

Gastrectomy with D2 Lymphadenectomy for Carcinoma of the Stomach in a Stand-alone Cancer Centre in Rural India

An R0 resection with D2 lymphadenectomy for gastric cancer carries acceptable morbidity and mortality in Indian patients with survival rates comparable with the western studies.

Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial.

  • M. DegiuliM. Sasako F. Calvo
  • Medicine
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • 2004

Improved survival after resectable non-cardia gastric cancer in The Netherlands: the importance of surgical training and quality control.

Patient survival after D 1 and D 2 resections for gastric cancer: long-term results of the MRC randomized surgical trial

The findings indicate that the classical Japanese D2 resection offers no survival advantage over D1 surgery, however, the possibility that D 2 resection without pancreatico-splenectomy may be better than standard D1 resection cannot be dismissed by the results of this trial.

Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer

A survival benefit for pancreas-preserving D2 dissection in Italian patients with gastric cancer if performed in experienced centres is suggested, and a phase III study comparing D1 vs D1 dissection for curable Gastric cancer is urgently needed.

Low Maruyama Index Surgery for Gastric Cancer: Blinded Reanalysis of the Dutch D1-D2 Trial

It is concluded that in this trial low- MI surgery is associated with enhanced survival, whereas outside of certain subgroups routine D2 lymphadenectomy is not, suggesting that surgeons might have more of an impact on patient survival by achieving a low-MI operation than a particular D level.

Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: The effect of undertreatment

MI, a measure of unresected regional nodal disease in gastric cancer, proved an independent predictor of survival, and surgical undertreatment, as observed in this trial, clearly undermined survival.

Extended lymph-node dissection for gastric cancer.

The results in Dutch patients do not support the routine use of D2 lymph-node dissection in patients with gastric cancer, as recommended by the Japanese medical community.

Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial.

  • R. SchwarzDavid D. Smith
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005